TScan Therapeutics (TCRX) Stock Forecast & Price Target

Compare

257 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

TCRX Analyst Ratings

Strong Buy

6 Buy

0 Hold

0 Sell

Based on 6 analysts giving stock ratings to

TScan

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

TCRX Stock 12 Month Forecast

Average Price Target

$8.60

▲(350.26% Upside)

Based on 6 Wall Street analysts offering 12 month price targets for TScan Therapeutics in the last 3 months. The average price target is $8.60 with a high forecast of $12.00 and a low forecast of $3.00. The average price target represents a 350.26% change from the last price of $1.91.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","13":"$13","3.25":"$3.25","6.5":"$6.5","9.75":"$9.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$8.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$3.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,3.25,6.5,9.75,13],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.62,2.418461538461538,3.2169230769230768,4.015384615384615,4.813846153846153,5.6123076923076916,6.4107692307692306,7.209230769230769,8.007692307692306,8.806153846153844,9.604615384615382,10.40307692307692,11.201538461538462,{"y":12,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.62,2.1569230769230767,2.693846153846154,3.230769230769231,3.7676923076923075,4.304615384615384,4.841538461538461,5.378461538461538,5.915384615384615,6.452307692307691,6.989230769230768,7.5261538461538455,8.063076923076922,{"y":8.6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.62,1.7261538461538461,1.8323076923076924,1.9384615384615385,2.0446153846153847,2.1507692307692308,2.256923076923077,2.363076923076923,2.4692307692307693,2.5753846153846154,2.6815384615384614,2.787692307692308,2.8938461538461535,{"y":3,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.62,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.55,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.83,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.98,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.95,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.85,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.04,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.1,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.27,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.55,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.46,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.43,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.62,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$12.00

Average Price Target$8.60

Lowest Price Target$3.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Sam Slutsky

LifeSci Capital

$12→$9

Buy

371.20%

Upside

Reiterated

08/14/25

OUTPERFORM | PRICE TARGET: $9.00 and we are adjusting our TScan price target to $9/share from $12/share.

Peter Lawson

Barclays

Buy

57.07%

Upside

Reiterated

08/13/25

TScan Therapeutics (TCRX) Gets a Buy from Barclays

Andres Y. Maldonado

H.C. Wainwright

$10

Buy

423.56%

Upside

Reiterated

08/12/25

Strategic Advancements and Promising Trial Data Propel TScan Therapeutics to 'Buy' Rating

Tara Bancroft

TD Cowen

―

Buy

―

Reiterated

08/12/25

TScan Therapeutics (TCRX) Gets a Buy from TD Cowen

Gil Blum

Needham

Buy

371.20%

Upside

Reiterated

08/12/25

Analysts Offer Insights on Healthcare Companies: TScan Therapeutics (NASDAQ: TCRX), Mereo Biopharma Group Plc (NASDAQ: MREO) and Oruka Therapeutics (NASDAQ: ORKA)

Justin Zelin

BTIG

$12

Buy

528.27%

Upside

Reiterated

08/11/25

TScan Therapeutics: Promising Developments and Strategic Advancements Drive Buy RatingWe value TCRX with a DCF analysis using a 12% DR and 2% TGR 738-6189 400-5178 Cap (M) $84.20 Shares Out (M) 52.30 Months (M) 0.56 CY25E REV 3.70 6.20 CY26E REV 0.00 0.00 Revenue (M) CY Q1 - - - Q2 - - - Q3 - - - Q4 - - - CY REV 2.80 6.20 0.00 EPS (GAAP) CY Q1 - - - Q2 - - - Q3 - - - Q4 - - - CY EPS (1.14) (1.18) (1.19).

Maxwell Skor

Morgan Stanley

$10

Buy

423.56%

Upside

Reiterated

05/19/25

Morgan Stanley Keeps Their Buy Rating on TScan Therapeutics (TCRX)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Sam Slutsky

LifeSci Capital

$12→$9

Buy

371.20%

Upside

Reiterated

08/14/25

OUTPERFORM | PRICE TARGET: $9.00 and we are adjusting our TScan price target to $9/share from $12/share.

Peter Lawson

Barclays

Buy

57.07%

Upside

Reiterated

08/13/25

TScan Therapeutics (TCRX) Gets a Buy from Barclays

Andres Y. Maldonado

H.C. Wainwright

$10

Buy

423.56%

Upside

Reiterated

08/12/25

Strategic Advancements and Promising Trial Data Propel TScan Therapeutics to 'Buy' Rating

Tara Bancroft

TD Cowen

―

Buy

―

Reiterated

08/12/25

TScan Therapeutics (TCRX) Gets a Buy from TD Cowen

Gil Blum

Needham

Buy

371.20%

Upside

Reiterated

08/12/25

Analysts Offer Insights on Healthcare Companies: TScan Therapeutics (NASDAQ: TCRX), Mereo Biopharma Group Plc (NASDAQ: MREO) and Oruka Therapeutics (NASDAQ: ORKA)

Justin Zelin

BTIG

$12

Buy

528.27%

Upside

Reiterated

08/11/25

Maxwell Skor

Morgan Stanley

$10

Buy

423.56%

Upside

Reiterated

05/19/25

Morgan Stanley Keeps Their Buy Rating on TScan Therapeutics (TCRX)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering TScan Therapeutics

1 Month

xxx

Success Rate

4/8 ratings generated profit

Average Return

-1.81%

reiterated a xxx

rating 26 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of -1.81% per trade.

3 Months

xxx

Success Rate

5/12 ratings generated profit

Average Return

-8.33%

reiterated a xxx

rating 24 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 41.67% of your transactions generating a profit, with an average return of -8.33% per trade.

1 Year

Gil BlumNeedham

Success Rate

3/8 ratings generated profit

Average Return

-24.07%

reiterated a buy rating 26 days ago

Copying Gil Blum's trades and holding each position for 1 Year would result in 37.50% of your transactions generating a profit, with an average return of -24.07% per trade.

2 Years

xxx

Success Rate

3/8 ratings generated profit

Average Return

-23.26%

reiterated a xxx

rating 26 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 37.50% of your transactions generating a profit, with an average return of -23.26% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

TCRX Analyst Recommendation Trends

Rating

Apr 25

May 25

Jun 25

Jul 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, TCRX has received 6 Buy Ratings, 13 Hold Ratings, and 0 Sell Ratings. TCRX average Analyst price target in the past 3 months is 8.60.

Each month's total comprises the sum of three months' worth of ratings.

TCRX Financial Forecast

TCRX Earnings Forecast

Next quarter’s earnings estimate for TCRX is -$0.33 with a range of -$0.57 to -$0.27. The previous quarter’s EPS was -$0.28. TCRX beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.17% of the time in the same period. In the last calendar year TCRX has Outperformed its overall industry.

TCRX Sales Forecast

Next quarter’s sales forecast for TCRX is $1.98M with a range of $500.00K to $2.50M. The previous quarter’s sales results were $3.08M. TCRX beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 47.33% of the time in the same period. In the last calendar year TCRX has Outperformed its overall industry.

TCRX Stock Forecast FAQ

What is TCRX’s average 12-month price target, according to analysts?

Based on analyst ratings, TScan Therapeutics’s 12-month average price target is 8.60.

What is TCRX’s upside potential, based on the analysts’ average price target?

TScan Therapeutics has 350.26% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is TCRX a Buy, Sell or Hold?

TScan Therapeutics has a consensus rating of Strong Buy which is based on 6 buy ratings, 0 hold ratings and 0 sell ratings.

What is TScan Therapeutics’s price target?

The average price target for TScan Therapeutics is 8.60. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $12.00 ,the lowest forecast is $3.00. The average price target represents 350.26% Increase from the current price of $1.91.

What do analysts say about TScan Therapeutics?

TScan Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.

How can I buy shares of TCRX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

TScan Therapeutics (TCRX) Stock Forecast & Price Target

TCRX Analyst Ratings

TCRX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering TScan Therapeutics

TCRX Analyst Recommendation Trends

TCRX Financial Forecast

TCRX Earnings Forecast

TCRX Sales Forecast

TCRX Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts